Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Otis W. Brawley"'
Autor:
Otis W. Brawley, Jeromie Ballreich, Lin Wang, Hwanhee Hong, Channing J. Paller, G. Caleb Alexander
Publikováno v:
Value Health
Objectives To assess the cost-effectiveness of systemic treatments for metastatic castration-sensitive prostate cancer from the US healthcare sector perspective with a lifetime horizon. Methods We built a partitioned survival model based on a network
Autor:
Otis W. Brawley
Publikováno v:
Urologic Clinics of North America. 30:331-335
Given that no therapy for localized prostate cancer has been proven superior to any other in well-designed clinical trials, the patient and physician may be influenced toward a particular therapy by a number of nonmedical factors. These factors can b
Autor:
Patricia Davis, David J. Liewehr, David R. Kohler, William D. Figg, Toni Wells-jones, William L. Dahut, Nehal Lakhani, Eddie Reed, Seth M. Steinberg, Otis W. Brawley, Michael Hamilton, Paul H. Duray
Publikováno v:
Acta Oncologica. 42:195-201
In this phase I/II clinical trial the antitumor activity of high-dose tamoxifen when administered in combination with vinblastine was assessed and the toxicity profile of this combination characterized. All 25 patients enrolled in this study were req
Autor:
Otis W. Brawley, Edward L. Trimble, Richard Ungerleider, M Smith, Nancy Breen, Warren B. Sateren, Leslie G. Ford, Jeffrey Abrams, Mary S. McCabe, Michaele C. Christian, Richard Kaplan
Publikováno v:
Journal of Clinical Oncology. 20:2109-2117
PURPOSE: We chose to examine the impact of socioeconomic factors on accrual to National Cancer Institute (NCI)–sponsored cancer treatment trials. PATIENTS AND METHODS: We estimated the geographic and demographic cancer burden in the United States a
Autor:
Polly Feigl, Otis W. Brawley, John Crowley, Brent A. Blumenstein, Charles A. Coltman, Ian M. Thompson, Barnett S. Kramer, Michael Wolf, Leslie G. Ford
Publikováno v:
Controlled Clinical Trials. 16:150-163
The PCPT is a chemoprevention trial of finasteride with a primary endpoint of biopsy-proven presence or absence of prostate cancer. A total of 18,000 healthy men, aged 55 years and older, will be randomized. Half will receive finasteride (5 mg/day) a
Autor:
Richard B. Warnecke, Paul A. Godley, Dan Garson-angert, Arnold D. Kaluzny, Otis W. Brawley, James E. Shaw, Leslie G. Ford
Publikováno v:
JNCI Journal of the National Cancer Institute. 85:1945-1950
Background The Minority-Based Community Clinical Oncology Program (MBCCOP) was initiated in September 1990 to expand the National Cancer Institute's (NCI's) clinical trials network to minority populations. Institutions, organizations, and/or physicia
Publikováno v:
Annals of the New York Academy of Sciences. 952
The dramatic international variation in prostate cancer mortality rates suggest an environmental influence. This combined with a building understanding of the genetic mechanisms of carcinogenesis encourages a search for ways to prevent it. Androgenic
Autor:
Richard K. Severson, Richard S. Ungerleider, W. Archie Bleyer, Heriberto Tejeda, Leslie L. Robison, Julie A. Ross, Bradley H Pollock, Malcolm A. Smith, Sharon B. Murphy, Otis W. Brawley
Publikováno v:
The Journal of adolescent health : official publication of the Society for Adolescent Medicine. 21(6)
To determine whether adolescents with cancer, who in comparison to younger patients have a higher cancer incidence and lower mortality reduction, have equal access to national cancer clinical trials.The ethnic/racial distribution of 29,859 subjects20
Autor:
W A Bleyer, Heriberto Tejeda, Otis W. Brawley, Richard S. Ungerleider, Sharon B. Murphy, Malcolm A. Smith
Publikováno v:
Journal of pediatric hematology/oncology. 19(5)
Purpose: To determine the ethnic/racial distribution of patients entered in national pediatric cancer clinical trials relative to the patient population served. Methods: The ethnic/racial distribution of 29,134 patients
Autor:
Edward L. Trimble, Heriberto A. Tejeda, Otis W. Brawley, Leslie G. Ford, Sylvan B. Green, Joseph L. High, Richard S. Ungerleider, Michael A. Friedman
Publikováno v:
Journal of the National Cancer Institute. 88(12)
Background : The National Cancer Institute (NCI)-sponsored clinical trials cooperative groups place more than 25 000 American patients in treatment trials every year. Equal access and proportional representation of all races/ethnicities is desired. P